Haemonetics (HAE) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Haemonetics (HAE) has outperformed Penumbra (PEN) over the past year, gaining 134.3% versus a gain of 22.6%. Over five years, HAE leads with a +70.9% price change compared with +18.6% for PEN. Penumbra is the larger company by market cap ($12.51 billion vs $5.44 billion), about 2.3 times the size.
On valuation, Haemonetics trades at a lower forward P/E (20.5x vs 51.8x for Penumbra). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus 7.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | PEN |
|---|---|---|
| Share price | $119.47 | $317.52 |
| Market cap | $5.44B | $12.51B |
| 1-day change | +17.46% | +0.37% |
| YTD return | +49.06% | +2.13% |
| 1-year return | +134.35% | +22.62% |
| 5-year return | +70.89% | +18.59% |
| P/E ratio (TTM) | 57.71 | 78.01 |
| Forward P/E | 20.53 | 51.78 |
| EPS (TTM) | $2.07 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $1.40B |
| Revenue growth (YoY) | -1.97% | +17.50% |
| Net income (latest FY) | $97.31M | $177.69M |
| Gross margin | 59.04% | 67.14% |
| Operating margin | 11.75% | 13.48% |
| Net margin | 7.29% | 12.66% |
| 52-week high | $121.00 | $362.41 |
| 52-week low | $48.17 | $221.26 |
| Distance from 52-week high | -1.26% | -12.39% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -6.67% | +13.88% |
| Average volume | 715.68K | 348.57K |
| Shares outstanding | 45.50M | 39.39M |
| Employees | 3,009 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra is about 2.3 times larger than Haemonetics by market value ($12.51B vs $5.44B).
- HAE has outperformed PEN by 111.7 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (78.0x vs 57.7x trailing P/E).
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus 7.3 cents for Haemonetics.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs -1.97%).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
HAE vs PEN FAQ
Which is bigger, Haemonetics or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.51B compared with $5.44B for Haemonetics (HAE).
Which stock has performed better over the past year, HAE or PEN?
HAE returned +134.35% over the past 12 months, compared with +22.62% for PEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or PEN?
HAE has the lower trailing P/E at 57.7, versus 78.0 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Haemonetics and Penumbra in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.